Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Price Target of $23.40 According to Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned a consensus recommendation of “Hold” from the eighteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $23.67.

Several equities analysts have recently commented on SRPT shares. Royal Bank Of Canada upped their price objective on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the stock a “sector perform” rating in a report on Friday, November 6th. William Blair upgraded Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Wall Street Zen downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Deutsche Bank raised Sarepta Therapeutics from a “sell” rating to a “hold” rating and raised their target price for the stock from $14.00 to $18.00 in a research report on Tuesday. Finally, HC Wainwright restated a “sell” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 5th.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $16.68 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.13 and a current ratio of 3.46. The stock’s fifty day moving average is $18.87 and its two-hundred day moving average is $18.57. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $24.68. The firm has a market capitalization of $1.79 billion, a P/E ratio of -12.18, a price-to-earnings-growth ratio of 0.39 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $381.35 million for the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The firm’s quarterly revenue was down 4.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.13) earnings per share. On average, research analysts anticipate that Sarepta Therapeutics will post 3.27 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. BlackRock Inc. purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $341,339,000. First Trust Advisors LP lifted its position in shares of Sarepta Therapeutics by 107.6% during the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after acquiring an additional 2,143,211 shares during the period. Bank of America Corp DE lifted its position in shares of Sarepta Therapeutics by 26.6% during the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after acquiring an additional 450,336 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Sarepta Therapeutics by 43.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,665,078 shares of the biotechnology company’s stock worth $36,232,000 after acquiring an additional 505,500 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $17,494,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.